

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Union Medical Healthcare Limited

香港醫思醫療集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2138)

- (1) ELECTION OF NON-EXECUTIVE DIRECTOR;**
- (2) RE-DESIGNATION OF DIRECTOR;**
- (3) RESIGNATION OF EXECUTIVE DIRECTOR;**
- (4) CHANGE OF CHIEF FINANCIAL OFFICER; AND**
- (5) CHANGE OF AUTHORIZED REPRESENTATIVE**

The Board is pleased to announce that:

1. Dr. Wang David Guowei was elected as a non-executive director of the Company at the AGM;
2. Mr. Luk Kun Shing Ben was re-designated from executive director to non-executive of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board);
3. Mr. Yeung Chin Wan has resigned as the executive director of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board);
4. Mr. Yeung Chin Wan has resigned as chief financial officer of the Company, and Mr. Law Man Tat was appointed as chief financial officer of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board); and
5. Mr. Yeung Chin Wan has also ceased to be an authorized representative of the Company and Mr. Siu Chun Pong Raymond, the current company secretary of the Company, was appointed as an authorized representative of the Company

with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board).

The board of directors (the “**Board**”) of Union Medical Healthcare Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that:

1. Dr. Wang David Guowei was elected as a non-executive director of the Company by way of ordinary resolutions passed at the annual general meeting of the Company held on 20 August 2018 (the “**AGM**”);
2. Mr. Luk Kun Shing Ben was re-designated from executive director to non-executive of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board);
3. Mr. Yeung Chin Wan has resigned as the executive director of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board);
4. Mr. Yeung Chin Wan has also resigned as chief financial officer of the Company, and Mr. Law Man Tat was appointed as chief financial officer of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board); and
5. Mr. Yeung Chin Wan has also ceased to be an authorized representative of the Company and Mr. Siu Chun Pong Raymond, the current company secretary of the Company, was appointed as an authorized representative of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board) .

ELECTION OF NON-EXECUTIVE DIRECTOR

Dr. Wang David Guowei (王國璋) (“**Dr. Wang**”), was elected as a non-executive director of the Company by way of ordinary resolutions passed at the AGM.

Dr. Wang, aged 56, has over 10 years of experience in the medical industry. Dr. Wang is the senior managing director of Asia at OrbiMed Advisors LLC, an investment fund with a focus on healthcare industry, where he has worked from August 2011. Dr. Wang was a director of Response Biomedical Corp. (Stock Code: RBM), a company listed on the Toronto Stock Exchange, from October 2011 to May 2015. From April 2006 to July 2011, he served as managing director at WI Harper Group, responsible for investment activities in life sciences and healthcare areas. From March 2010 to July 2012, he served on the board of directors of Edan instruments, Inc. (a company listed on the Shenzhen

Stock Exchange, stock code: 300206), a provider of advanced electronic medical equipments where he also served on both the audit committee and strategic committee. Dr. Wang is now serving on the board of directors of Suzhou Medical System Technology Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603990), serving on the boards of directors of Amoy Diagnostics Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 300685), and serving on the boards of directors of AK Medical Holdings Limited (a company listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), stock code: 1789).

Dr. Wang received his doctorate in developmental biology from California Institute of Technology in June 1995. He received his bachelor degree in medicine from Beijing Medical University (北京醫科大學) (currently known as Peking University Health Science Centre (北京大學醫學部) in July 1986.

The Company has entered into a letter of appointment with Dr. Wang for an initial term of three years commencing from 20 August 2018. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company. Pursuant to the letter of appointment entered into between the Company and Dr. Wang, the director’s fee of Dr. Wang will be HK\$120,000 per annum which is determined with reference to his expected duties and responsibilities and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Dr. Wang (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other positions with the Company or other members of the Group; (iii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iv) does not hold any other major appointment and qualifications; and (v) does not have any relationships with any Directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Dr. Wang confirms that there are no other matters or information that needs to be brought to the attention of the holders of securities of the Company or needs to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules.

RE-DESIGNATION OF DIRECTOR

Due to his other career commitment, Mr. Luk Kun Shing Ben (陸韻晟) (“**Mr. Luk**”), who was an executive director of the Company since September 2015, was re-

designated as a non-executive director of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board) and will continue to provide advice to the Board.

Mr. Luk, aged 39, has more than 6 years of experience in the aesthetic medical industry, and over 14 years of experience in the information technology industry. Prior to joining our Group in March 2010, from January 2011 to February 2014, Mr. Luk served as a software engineer at Google (Hong Kong) Limited, a subsidiary of Google Inc., specialising in internet-related services and products. From December 2003 to December 2010, he was a software engineer at Google Inc., in Mountain View, California, the United States and involved in the implementation of Google Maps. Mr. Luk graduated from Cornell University with a bachelor of science degree in computer science in August 2000 and Stanford University with a master of science degree in computer science in June 2003.

Mr. Luk was appointed as the Engineering Site Lead at Google Beijing. The Board congratulates Mr. Luk for taking up the said position. The Board believes that his role in Google Beijing will allow him to be in touch with the state-of-the-art technology and Mr. Luk will continue to advise the Company to enhance its IT systems and access to the latest IT resources.

The Company has entered into a letter of appointment as non-executive director with Mr. Luk for an initial term of three years commencing from 20 August 2018. He is subject to the retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company. Pursuant to the letter of appointment entered into between the Company and Mr. Luk, the director's fee of Mr. Luk will be HK\$120,000 per annum which is determined with reference to his expected duties and responsibilities and the prevailing market conditions.

Mr. Luk currently holds 2,487,500 shares of the Company, representing approximately 0.25% of the entire issued share capital of the Company as at the date of this announcement.

Save as disclosed above, as at the date of this announcement, Mr. Luk (i) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other positions with the Company or other members of the Group; (iii) did not hold any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (iv) does not hold any other major appointment and qualifications; and (v) does not have any relationships with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Save as disclosed above, Mr. Luk confirms that there are no other matters or information that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) or the holders of securities of the Company or needs to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules.

RESIGNATION OF EXECUTIVE DIRECTOR

Due to family reasons, Mr. Yeung Chin Wan (“**Mr. Yeung**”) has resigned as the executive director of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board).

Mr. Yeung has confirmed that he has no disagreement with the Board and there are no other matters in relation to his resignation that needs to be brought to the attention of the Stock Exchange or the holders of securities of the Company.

CHANGE OF CHIEF FINANCIAL OFFICER

With effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board), Mr. Yeung has also resigned as the chief financial officer of the Company and Mr. Law Man Tat (“**Mr. Law**”) has been appointed as chief financial officer of the Company. Mr. Law has been working in the Company since August 2017.

CHANGE OF AUTHORIZED REPRESENTATIVE

In connection with the resignation of Mr. Yeung, Mr. Yeung has also ceased to be an authorized representative of the Company with effect from 20 August 2018 (after the conclusion of the AGM and the subsequent meeting of the Board) and Siu Chun Pong Raymond, the current company secretary of the Company, has been appointed as the authorized representative of the Company (for the purposes of Listing Rules and Companies Ordinance (Cap. 622 of the Laws of Hong Kong)) on the same date.

The Board would like to express its sincere gratitude to Mr. Yeung for his valuable contributions to the Company during their tenure with the Company and extend its warm welcome to Dr. Wang and Mr. Law for their new appointment.

Reference is made to the circular of the Company dated 20 August 2018. All list of directors as referred to in the said circular (including the notice of extraordinary general meeting therein) refer to the directors of the Company as at the latest practicable date as stated therein (i.e. 14 August 2018).

By Order of the Board of
Union Medical Healthcare Limited
Lee Gabriel
Executive Director

Hong Kong, 20 August 2018

As at the date of this announcement and after the AGM and the subsequent board meeting approving all other changes of Directors, the board of Directors comprises two executive directors, namely Mr. Tang Chi Fai and Mr. Lee Gabriel; two non-executive Directors, namely Mr. Luk Kun Shing Ben and Dr. Wang David Guowei, and three independent non-executive directors, namely Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Lam Chi Hang Josekin.

**For identification purpose only*